Month: February 2021
OREM, Utah, Feb. 23, 2021 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for biotechnology, pharmaceutical, and transportation industries, announces a 23.7% year over year fourth quarter increase in sales.The 2020 fourth quarter sales of $695,823 showed an increase of 23.7% over the fourth quarter sales of $562,314 in 2019. These figures represent total fourth quarter sales for the company, although the largest contributor to this increase was the Cryometrix ULT freezer product line. Mr. Kim Boyce, CEO of Reflect Scientific Inc, commented, “We ended the year on a high note. Overall we were delighted with the sales for the fourth quarter of 2020.”About Reflect Scientific, Inc.Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies...
Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021Escalated the Dose in RTX-240 Phase 1 Clinical Trial in Relapsed/Refractory Acute Myeloid LeukemiaScreening Patients in RTX-321 Phase 1 Clinical Trial in Advanced Human Papillomavirus 16-Positive CancersCAMBRIDGE Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported fourth quarter and full year 2020 financial results and provided a business update.“Last year was one of strong execution for Rubius Therapeutics as we advanced our clinical trials in oncology and...
ORYZON Reports Results and Corporate Update for 4th Quarter and Year Ended December 31, 2020
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
MADRID, Spain and CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2020 and provided an update on recent developments.Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon made strong progress in 2020, achieving a number of important clinical milestones that further our pioneering work in personalized medicine in epigenetics. New clinical data in acute myeloid leukemia corroborate the strong clinical activity of iadademstat and signals a clear path ahead for the development of the molecule in oncology. In CNS, the regulatory green light to start our first Phase IIb study in borderline...
MedX Holdings Inc. Acquires Smart Brands Digital to Manage Brand Visibility
Written by Customer Service on . Posted in Public Companies.
CHEYENNE, Wyo., Feb. 23, 2021 (GLOBE NEWSWIRE) — MedX Holdings Inc. (OTC: MEDH) (“MEDH” or the “Company”), a brands management and acquisition company, today announces it has acquired Smart Brands Digital, LLC as a wholly owned subsidiary.Smart Brands Digital, a Texas company, will be responsible for the online product marketing and brand awareness of MEDH’s various hemp and cannabidiol (CBD) products and initiatives.The Company intends to announce additional subsidiaries in the near future, following the release of its upcoming annual report.MedX Holdings Inc. (OTC: MEDH) is a brands and acquisition company. Our vision is to develop brands and the ancillary infrastructure needed to create demand through vertical integration, strategic partnerships, licensing, franchising, as well as to provide solutions to the emerging hemp and...
Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021.Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development and operational execution. She is currently the Chief Operating Officer of Mesoblast Limited. Ms. Rosa-Bjorkeson has led multiple successful product launches, including Gilenya® for multiple sclerosis at Novartis where she was Vice President and Head of its multiple sclerosis business unit, Vice President, Business...
Qorvo® to Present at the Raymond James 42nd Annual Institutional Investors Conference
Written by Customer Service on . Posted in Public Companies.
GREENSBORO, N.C., Feb. 23, 2021 (GLOBE NEWSWIRE) — Qorvo® (Nasdaq: QRVO), a leading provider of innovative RF solutions that connect the world, today announced that Company executives are scheduled to present at the Raymond James 42nd Annual Institutional Investors Conference on Tuesday, March 2, 2021 at 9:10 a.m. ET.A live webcast of the virtual event will be available on the Company’s web site at the following URL: http://www.qorvo.com (under “Investors”).About QorvoQorvo (Nasdaq: QRVO) makes a better world possible by providing innovative Radio Frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of...
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
Written by Customer Service on . Posted in Public Companies.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor conferences:Cowen & Co. 41stAnnual Health Care Conference: A panel discussion will be available live to conference attendees on Monday, March 1, 2021 at 10:30 a.m. ET.42ndAnnual Raymond James Institutional Investors Conference: A live webcast fireside chat will take place on Tuesday, March 2, 2021 at 3:50 p.m. ET.H.C. Wainwright Global Life Sciences Conference: A webcast presentation will be available on demand during the conference, starting Tuesday, March 9, 2021 at 7:00 a.m. ET.33rdAnnual ROTH Conference: A live webcast panel discussion...
B2Digital Prepares for Biggest Weekend in Company History, Featuring Three Live Events
Written by Customer Service on . Posted in Public Companies.
Tampa, FL, Feb. 23, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is excited to announce the Company will move into uncharted territory this weekend with three separate live events all occurring over the same weekend.“This weekend will feature three big events across two major venues and should certainly represent our biggest single weekend in Company history,” remarked Greg P. Bell, Chairman & CEO of B2Digital. “We should also benefit from cost efficiencies due to multiple events sharing fixed cost profiles around overhead.”The weekend will feature two separate B2 Fighting Series live events in Bowling Green, Kentucky – one on Friday, February 26, and one on Saturday, February 27. Saturday...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Written by Customer Service on . Posted in Public Companies.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:00 a.m. ET on Thursday, March 4, 2021, to discuss its fourth quarter and full year 2020 financial results and provide a business update.The webcast of the conference call may be accessed by visiting the “Events” section in the Investor Relations page of the Wave Life Sciences website at www.wavelifesciences.com. The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 6269069. Following the conference call, an archived version of the call will be available...
Annual General Meeting in ALK-Abelló A/S on 18 March 2021
Written by Customer Service on . Posted in Public Companies.
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The Annual General Meeting of ALK-Abelló A/S will be held on Thursday 18 March 2021 at 4.00pm (CET) as a fully electronic Annual General Meeting. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.Shareholders who have registered their attendance can participate in the Annual General Meeting via VP’s VGM portal. The Annual General Meeting will also be webcast live at ALK’s website: https://ir.alk.net/agm.ALK-Abelló A/SFor further information please contact:Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525Media: Jeppe Ilkjær, mobile +45 3050 2014About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services...
